SEC Form 4 · accession 0001179110-17-011478
Theravance Biopharma, Inc. · TBPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Burton G Malkiel
Director
Period of report
Aug 11, 2017
Accepted (ET)
Aug 14, 2017 · 7:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001583107
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Aug 11, 2017 | P | 15,000 | $24.5903 | A | 47,571 | D | |
| Ordinary SharesF2 | Aug 11, 2017 | P | 15,000 | $24.5877 | A | 15,000 | I | By Spouse |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the weighted average purchase price per share for the open market purchase on August 11, 2017. The shares were purchased at prices ranging from $24.35 to $24.921 per share. Full information regarding the number of shares purchased at each price shall be provided upon request from the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F2Represents the weighted average purchase price per share for the open market purchase on August 11, 2017. The shares were purchased at prices ranging from $24.36 to $24.903 per share. Full information regarding the number of shares purchased at each price shall be provided upon request from the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.